HEALTHCARE

July 22, 2019

U.N. Environment Programme Urged to Protect Nature and Humankind from Electromagnetic Fields (EMF)

The Advisors to the International EMF Scientist Appeal, representing 248 scientists from 42 nations, have resubmitted The Appeal to the United Nations Environment Programme (UNEP) Executive Director, Inger Andersen, requesting the UNEP reassess the potential biological impacts of next generation"...

Read More >>

July 22, 2019

Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab as maintenance therapy in adult patients with moderately to severely active Crohns disease (CD) who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) therapy at weeks 0 and 2.1 In evaluating the primary endpoint of the trial, a statistically significant proportion of patients receiving vedolizumab SC achieved clinical remission**......

Read More >>

July 21, 2019

Health Ministry ceases overseas treatment.

The Ministry of Health announced Thursday the cessation of overseas treatment completely, after the resignation of the Chairman and members of the High Consultative Committee for Treatment Abroad.

The president"...

Read More >>

July 20, 2019

Embrace Family Planning to Tackle Population Explosion, Experts Warn Nigerians

The Bureau of Public Enterprises (BPE) is to privatise the 10 remaining National Integrated Power Projects (NIPPs) this year in a bid to bolster power supply in the country.

The BPE Director General, Mr. Alex"...

Read More >>

July 20, 2019

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective"...

Read More >>

July 18, 2019

Foreign Minister discusses with head of Audit Bureau overseas medical treatment file

President of the Audit Bureau, Khalid Shakshak discussed with Foreign Minister, Mohammed Sayala the file of the overseas medical treatment and the challenges encountered in this regard.

The two sides reviewed"...

Read More >>

July 18, 2019

AHF to WHO: Ebola Response, Too Little, Too Late!

The World Health Organization (WHO) has finally declared a Public Health Emergency of International Concern (PHEIC) in the Democratic Republic of the Congo on July 17 as a long overdue acknowledgement that the current Ebola outbreak remains uncontained and still poses a significant threat to global health security. A PHEIC declaration carries legal obligations requiring affected states to cooperate with the WHO in coordinating an outbreak response plan and also puts the global public health community on notice signifying a substantial health security risk to the world. “The PHEIC declaration is a step in the right direction, but it should......

Read More >>

July 18, 2019

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including"...

Read More >>

July 16, 2019

AHF: Clock Is Ticking, WHO – Act Now on Ebola!

With the first reported case of Ebola emerging this week in Goma, a populous city in the eastern Democratic Republic of the Congo (DRC) next to the Rwandan city of Gisenyi, medical care providers and public health advocates from AIDS Healthcare Foundation (AHF)"...

Read More >>

July 16, 2019

ResMed Inc. Completes $500M Private Placement Debt Offering

ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029.

Net"...

Read More >>

Found articles: - Pages